Skip to main content
Erschienen in: CME 1-2/2024

09.02.2024 | Prostatakarzinom | CME Fortbildung

Update Prostatakarzinom

Auf einen Kaffee mit ChatGPT

verfasst von: Fabian Falkenbach, Prof. Dr. med. Tobias Maurer

Erschienen in: CME | Ausgabe 1-2/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Prostatakrebs ist die am häufigsten diagnostizierte Tumorerkrankung des Mannes. Er nimmt mit fortschreitendem Alter an Bedeutung zu. Angesichts der hohen Prävalenz und der Tatsache, dass viele Männer ihren Hausarzt als primären Ansprechpartner für gesundheitliche Belange sehen, sind aktuelle Entwicklungen diesbezüglich gerade auch für hausärztliche Kollegen relevant. In diesem Artikel behandeln wir unter Zuhilfenahme von ChatGPT aktuelle Thematiken rund um das Prostatakarzinom von Früherkennung bis hin zum metastasierten Stadium. Gleichzeitig zeigen wir auf, wie künstliche Intelligenz die medizinische Weiterbildung erleichtern kann, aber auch welche Grenzen diese gegenwärtig (noch) aufweist.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland für 2017/2018. 13 ed2021. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland für 2017/2018. 13 ed2021.
2.
Zurück zum Zitat Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine. 2023;388(17):1547-58. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine. 2023;388(17):1547-58.
3.
Zurück zum Zitat Piazza P, Checcucci E, Puliatti S, Belenchòn IR, Veccia A, Rivas JG, et al. The Long but Necessary Journey Towards Optimization of the Cause-Effect Relationship Between Input and Output for Accountable Use of ChatGPT for Academic Purposes. European Urology Focus. Piazza P, Checcucci E, Puliatti S, Belenchòn IR, Veccia A, Rivas JG, et al. The Long but Necessary Journey Towards Optimization of the Cause-Effect Relationship Between Input and Output for Accountable Use of ChatGPT for Academic Purposes. European Urology Focus.
5.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043/022OL2021. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043/022OL2021.
6.
Zurück zum Zitat Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16.
7.
Zurück zum Zitat Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases. 2018;21(1):57-63. Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases. 2018;21(1):57-63.
8.
Zurück zum Zitat Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-77. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-77.
9.
Zurück zum Zitat Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU International. 2017;119(2):225-33. Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU International. 2017;119(2):225-33.
10.
Zurück zum Zitat Darst BF, Sheng X, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. Eur Urol. 2021;80(2):134-8. Darst BF, Sheng X, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. Eur Urol. 2021;80(2):134-8.
11.
Zurück zum Zitat Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, et al. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology. 2022;81(5):458-62. Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, et al. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology. 2022;81(5):458-62.
12.
Zurück zum Zitat Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;2013(1):Cd004720. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;2013(1):Cd004720.
13.
Zurück zum Zitat Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, et al. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. Eur Urol Oncol. 2023. Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, et al. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. Eur Urol Oncol. 2023.
14.
Zurück zum Zitat Arsov C, Albers P, Herkommer K, Gschwend J, Imkamp F, Peters I, et al. A randomized trial of risk-adapted screening for prostate cancer in young men - Results of the first screening round of the PROBASE trial. International Journal of Cancer. 2022;150(11):1861-9. Arsov C, Albers P, Herkommer K, Gschwend J, Imkamp F, Peters I, et al. A randomized trial of risk-adapted screening for prostate cancer in young men - Results of the first screening round of the PROBASE trial. International Journal of Cancer. 2022;150(11):1861-9.
15.
Zurück zum Zitat Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-22. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-22.
16.
Zurück zum Zitat Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100-9. Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100-9.
17.
Zurück zum Zitat Grönberg H, Eklund M, Picker W, Aly M, Jäderling F, Adolfsson J, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018;74(6):722-8. Grönberg H, Eklund M, Picker W, Aly M, Jäderling F, Adolfsson J, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018;74(6):722-8.
18.
Zurück zum Zitat Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020;23(1):136-43. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020;23(1):136-43.
19.
Zurück zum Zitat Lokeshwar SD, Syed JS, Segal D, Rahman SN, Sprenkle PC. Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer. Curr Oncol Rep. 2022;24(2):249-56. Lokeshwar SD, Syed JS, Segal D, Rahman SN, Sprenkle PC. Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer. Curr Oncol Rep. 2022;24(2):249-56.
20.
Zurück zum Zitat Vickers AJ. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. 2021;80(5):567-72. Vickers AJ. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. 2021;80(5):567-72.
21.
Zurück zum Zitat Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun. 2017;8:13671. Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun. 2017;8:13671.
22.
Zurück zum Zitat Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur Urol. 2015;68(2):186-93. Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur Urol. 2015;68(2):186-93.
23.
Zurück zum Zitat de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-102. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-102.
24.
Zurück zum Zitat Farashi S, Kryza T, Clements J, Batra J. Post-GWAS in prostate cancer: from genetic association to biological contribution. Nature Reviews Cancer. 2019;19(1):46-59. Farashi S, Kryza T, Clements J, Batra J. Post-GWAS in prostate cancer: from genetic association to biological contribution. Nature Reviews Cancer. 2019;19(1):46-59.
26.
Zurück zum Zitat Fendler WP, Hope TA, Jiang F, Thompson D, Barbato F, Juarez R, et al. Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers. Journal of Clinical Oncology. 2023;41(16_suppl):5011. Fendler WP, Hope TA, Jiang F, Thompson D, Barbato F, Juarez R, et al. Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers. Journal of Clinical Oncology. 2023;41(16_suppl):5011.
27.
Zurück zum Zitat Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403-17. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403-17.
28.
Zurück zum Zitat Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, et al. [(68)Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol. 2019;141:214-9. Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, et al. [(68)Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol. 2019;141:214-9.
29.
Zurück zum Zitat Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-16. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-16.
30.
Zurück zum Zitat Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, et al. Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol. 2012;62(2):333-40. Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, et al. Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol. 2012;62(2):333-40.
31.
Zurück zum Zitat Rocco B, Sarchi L, Assumma S, Cimadamore A, Montironi R, Reggiani Bonetti L, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. 2021;80(6):724-9. Rocco B, Sarchi L, Assumma S, Cimadamore A, Montironi R, Reggiani Bonetti L, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. 2021;80(6):724-9.
32.
Zurück zum Zitat Baas DJH, Vreuls W, Sedelaar JPM, Vrijhof H, Hoekstra RJ, Zomer SF, et al. Confocal laser microscopy for assessment of surgical margins during radical prostatectomy. BJU Int. 2022. Baas DJH, Vreuls W, Sedelaar JPM, Vrijhof H, Hoekstra RJ, Zomer SF, et al. Confocal laser microscopy for assessment of surgical margins during radical prostatectomy. BJU Int. 2022.
33.
Zurück zum Zitat Dinneen E, Grierson J, Almeida-Magana R, Clow R, Haider A, Allen C, et al. NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer. Trials. 2022;23(1):584. Dinneen E, Grierson J, Almeida-Magana R, Clow R, Haider A, Allen C, et al. NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer. Trials. 2022;23(1):584.
34.
Zurück zum Zitat Haese A, Knipper S, Isbarn H, Heinzer H, Tilki D, Salomon G, et al. A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures. BJU Int. 2019;123(6):1031-40. Haese A, Knipper S, Isbarn H, Heinzer H, Tilki D, Salomon G, et al. A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures. BJU Int. 2019;123(6):1031-40.
35.
Zurück zum Zitat Falkenbach F, Maurer T. PSMA-targeted fluorescence guidance for robotic-assisted prostatectomy. Nature Reviews Urology. 2023. Falkenbach F, Maurer T. PSMA-targeted fluorescence guidance for robotic-assisted prostatectomy. Nature Reviews Urology. 2023.
36.
Zurück zum Zitat Darr C, Costa PF, Kahl T, Moraitis A, Engel J, Al-Nader M, et al. Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens. European Urology Open Science. 2023;54:28-32. Darr C, Costa PF, Kahl T, Moraitis A, Engel J, Al-Nader M, et al. Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens. European Urology Open Science. 2023;54:28-32.
37.
Zurück zum Zitat Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. 2022. Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. 2022.
38.
Zurück zum Zitat Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018;74(4):455-62. Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018;74(4):455-62.
39.
Zurück zum Zitat Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650-9. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650-9.
40.
Zurück zum Zitat Deek MP, Eecken KVd, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. Journal of Clinical Oncology. 2022;40(29):3377-82. Deek MP, Eecken KVd, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. Journal of Clinical Oncology. 2022;40(29):3377-82.
41.
Zurück zum Zitat Tocco BR, Kishan AU, Ma TM, Kerkmeijer LGW, Tree AC. MR-Guided Radiotherapy for Prostate Cancer. Front Oncol. 2020;10:616291. Tocco BR, Kishan AU, Ma TM, Kerkmeijer LGW, Tree AC. MR-Guided Radiotherapy for Prostate Cancer. Front Oncol. 2020;10:616291.
42.
Zurück zum Zitat James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77.
43.
Zurück zum Zitat Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308-20. Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308-20.
44.
Zurück zum Zitat Royce TJ, Lee DH, Keum N, Permpalung N, Chiew CJ, Epstein S, et al. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials. Eur Urol Focus. 2019;5(4):577-84. Royce TJ, Lee DH, Keum N, Permpalung N, Chiew CJ, Epstein S, et al. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials. Eur Urol Focus. 2019;5(4):577-84.
45.
Zurück zum Zitat Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-66. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-66.
46.
Zurück zum Zitat Sivaraman A, Barret E. Focal Therapy for Prostate Cancer: An ‘‘A` la Carte'' Approach. European Urology. 2016;69(6):973-5. Sivaraman A, Barret E. Focal Therapy for Prostate Cancer: An ‘‘A` la Carte'' Approach. European Urology. 2016;69(6):973-5.
47.
Zurück zum Zitat Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence. 2022;1(9):EVIDoa2200043. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence. 2022;1(9):EVIDoa2200043.
48.
Zurück zum Zitat Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804.
49.
Zurück zum Zitat Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-103. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-103.
50.
Zurück zum Zitat Khene Z-E, Bigot P, Mathieu R, Rouprêt M, Bensalah K. Development of a Personalized Chat Model Based on the European Association of Urology Oncology Guidelines: Harnessing the Power of Generative Artificial Intelligence in Clinical Practice. European Urology Oncology. Khene Z-E, Bigot P, Mathieu R, Rouprêt M, Bensalah K. Development of a Personalized Chat Model Based on the European Association of Urology Oncology Guidelines: Harnessing the Power of Generative Artificial Intelligence in Clinical Practice. European Urology Oncology.
51.
Zurück zum Zitat May M, Körner-Riffard K, Marszalek M, Eredics K. Would Uro_Chat, a Newly Developed Generative Artificial Intelligence Large Language Model, Have Successfully Passed the In-Service Assessment Questions of the European Board of Urology in 2022? European Urology Oncology. May M, Körner-Riffard K, Marszalek M, Eredics K. Would Uro_Chat, a Newly Developed Generative Artificial Intelligence Large Language Model, Have Successfully Passed the In-Service Assessment Questions of the European Board of Urology in 2022? European Urology Oncology.
Metadaten
Titel
Update Prostatakarzinom
Auf einen Kaffee mit ChatGPT
verfasst von
Fabian Falkenbach
Prof. Dr. med. Tobias Maurer
Publikationsdatum
09.02.2024

Weitere Artikel der Ausgabe 1-2/2024

CME 1-2/2024 Zur Ausgabe

Medizin

Medizin